Skip to main content
SpringerLink
Log in

Sklerosierende Hauterkrankungen

Sclerosing skin diseases

  • Schwerpunkt: Dermatologie und Innere Medizin
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Sklerosierende Hautveränderungen sind eher Symptom als Diagnose und müssen daher sorgfältig abgeklärt werden. Die systemische Sklerodermie als Multiorganerkrankung ist von der zirkumskripten Sklerodermie zu trennen, da sie neben einem unterschiedlichen klinischen Bild eine unterschiedliche Prognose hat und ein anderes therapeutisches Vorgehen erfordert. Seltenere sklerosierende Hauterkrankungen mit Implikationen für die innere Medizin, die im vorliegenden Beitrag besprochen werden, sind die eosinophile Fasziitis, das Scleroedema adultorum Buschke, das Skleromyxödem und die nephrogene Fibrose.

Abstract

Sclerosing skin manifestations are more a symptom than a diagnosis and must therefore be meticulously clarified. Systemic scleroderma as a multiorgan disease must be distinguished from localized scleroderma or morphea because in addition to a different clinical picture they have a different prognosis and necessitate other therapeutic procedures. Rare sclerosing skin diseases with implications for internal medicine are eosinophilic fasciitis, Buschke’s scleredema adultorum, scleromyxedema and nephrogenic systemic fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L (2017) Cutaneous manifestations of scleroderma and Scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol 53:306–336

    Article  CAS  Google Scholar 

  2. Jendrek ST, Kahle B, Riemekasten G (2019) Mimetics of systemic sclerosis. Z Rheumatol 78:14–23

    Article  CAS  Google Scholar 

  3. Pearson DR, Werth VP, Pappas-Taffer L (2018) Systemic sclerosis: current concepts of skin and systemic manifestations. Clin Dermatol 36:459–474

    Article  Google Scholar 

  4. Sticherling M (2012) Systemic sclerosis—focus on dermatological aspects. Part 2:diagnostics, therapy. J Dtsch Dermatol Ges 10:783–791

    PubMed  Google Scholar 

  5. Sticherling M (2012) Systemic sclerosis-dermatological aspects. Part 1:Pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges 10:705–718 (quiz 716)

    PubMed  Google Scholar 

  6. Kucharz EJ, Kopeć-Mędrek M (2017) Systemic sclerosis sine scleroderma. Adv Clin Exp Med 26:875–880

    Article  Google Scholar 

  7. Knobler R, Moinzadeh P, Hunzelmann N et al (2017) European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol 31:1401–1424

    Article  CAS  Google Scholar 

  8. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816–827

    Article  CAS  Google Scholar 

  9. Distler O, Cozzio A (2016) Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy. Semin Immunopathol 38:87–95

    Article  CAS  Google Scholar 

  10. Sticherling M (2019) Systemische Sklerodermie – die dermatologische Sicht (Systemic scleroderma – the dermatological view). J Dtsch Dermatol Ges. 2019 (in press)

  11. Tartar DM, Chung L, Fiorentino DF (2018) Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. Clin Dermatol 36:508–524

    Article  Google Scholar 

  12. Volkmann ER, Varga J (2019) Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol 15:208–224

    Article  Google Scholar 

  13. Riemekasten G (2019) Progress in systemic sclerosis—early, targeted and intensive therapy is the key to success. Dtsch Med Wochenschr 144:189–193

    Article  Google Scholar 

  14. Hunzelmann N (2018) Current treatment of systemic scleroderma. Hautarzt 69:901–907

    Article  Google Scholar 

  15. Orlandi M, Barsotti S, Lepri G, Codullo V, Di Battista M, Guiducci S, Rossa DA (2018) One year in review 2018: systemic sclerosis. Clin Exp Rheumatol 36(Suppl 113):3–23

    PubMed  Google Scholar 

  16. Kreuter A, Krieg T, Worm M et al (2009) AWMF Guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma. J Dtsch Dermatol Ges 7(Suppl 6):1–14

    Google Scholar 

  17. Fett N, Werth VP (2011) Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 64:217–228

    Article  Google Scholar 

  18. Takehara K, Sato S (2005) Localized scleroderma is an autoimmune disorder. Baillieres Clin Rheumatol 44:274–279

    CAS  Google Scholar 

  19. Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ (2017) Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol 18:491–512

    Article  Google Scholar 

  20. Das J, Chinoy H, Dick J, Matthews R, Roberts M (2017) A literature review of eosinophilic fasciitis with an illustrative case. Curr Rheumatol Rev 13:113–120

    Article  Google Scholar 

  21. Ihn H (2019) Eosinophilic fasciitis: From pathophysiology to treatment. Allergol Int. https://doi.org/10.1016/j.alit.2019.03.001

    Article  PubMed  Google Scholar 

  22. Mazori DR, Femia AN, Vleugels RA (2017) Eosinophilic fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep 19:74

    Article  Google Scholar 

  23. Sène D (2015) Eosinophilic fasciitis (Shulman’s disease): diagnostic and therapeutic review. Rev Med Interne 36:738–745

    Article  Google Scholar 

  24. Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T (2017) European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol 31:1581–1594

    Article  CAS  Google Scholar 

  25. Kreuter A (2018) Scleredema adultorum: Clinical presentation, diagnostic workup, differential diagnosis, treatment option. Hautarzt 69:908–915

    Article  CAS  Google Scholar 

  26. Beers WH, Ince A, Moore TL (2006) Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 35:355–359

    Article  Google Scholar 

  27. Miguel D, Schliemann S, Elsner P (2018) Treatment of scleroedema Adultorum Buschke: a systematic review. Acta Derm Venereol 98:305–309

    Article  Google Scholar 

  28. Kirchberger MC, Sticherling M, Erdmann M (2017) Uncommon presentation of scleromyxoedema with a distribution pattern mimicking a photodermatosis. Acta Derm Venereol 97:979–980

    Article  Google Scholar 

  29. Neufeld M, Sunderkötter C, Moritz RKC (2018) Scleromyxedema. Hautarzt 69:916–921

    Article  CAS  Google Scholar 

  30. Raczeck P, Fries P, Bücker A, Schneider G (2019) Gadolinium deposition-“gadolinium deposition disease”. Radiologe 59:435–443

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hautklinik, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland

    Michael Sticherling

Authors
  1. Michael Sticherling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Sticherling.

Ethics declarations

Interessenkonflikt

M. Sticherling gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Additional information

Redaktion

H. Haller, Hannover

T. Werfel, Hannover

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sticherling, M. Sklerosierende Hauterkrankungen. Internist 60, 783–791 (2019). https://doi.org/10.1007/s00108-019-0643-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-019-0643-2

Schlüsselwörter

Keywords

Search

Navigation